These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34967562)

  • 21. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer.
    Lin PH; Kuo WH; Huang AC; Lu YS; Lin CH; Kuo SH; Wang MY; Liu CY; Cheng FT; Yeh MH; Li HY; Yang YH; Hsu YH; Fan SC; Li LY; Yu SL; Chang KJ; Chen PL; Ni YH; Huang CS
    Oncotarget; 2016 Feb; 7(7):8310-20. PubMed ID: 26824983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.
    Ong PY; Poon SL; Tan KT; Putti TC; Ow SGW; Chen SJ; Chen CH; Lee SC
    Gynecol Oncol; 2019 Nov; 155(2):275-279. PubMed ID: 31481248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation.
    Vietri MT; D'Elia G; Caliendo G; Albanese L; Signoriello G; Napoli C; Molinari AM
    Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Germline Genetic Features of Young Individuals With Colorectal Cancer.
    Stoffel EM; Koeppe E; Everett J; Ulintz P; Kiel M; Osborne J; Williams L; Hanson K; Gruber SB; Rozek LS
    Gastroenterology; 2018 Mar; 154(4):897-905.e1. PubMed ID: 29146522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
    Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
    BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular analysis of the APC and MUTYH genes in Galician and Catalonian FAP families: a different spectrum of mutations?
    Gómez-Fernández N; Castellví-Bel S; Fernández-Rozadilla C; Balaguer F; Muñoz J; Madrigal I; Milà M; Graña B; Vega A; Castells A; Carracedo A; Ruiz-Ponte C
    BMC Med Genet; 2009 Jun; 10():57. PubMed ID: 19531215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.
    Muller KE; Marotti JD; de Abreu FB; Peterson JD; Miller TW; Chamberlin MD; Tsongalis GJ; Tafe LJ
    Exp Mol Pathol; 2016 Jun; 100(3):421-5. PubMed ID: 27095739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of oncogenesis in colon versus rectal cancer.
    Kapiteijn E; Liefers GJ; Los LC; Kranenbarg EK; Hermans J; Tollenaar RA; Moriya Y; van de Velde CJ; van Krieken JH
    J Pathol; 2001 Sep; 195(2):171-8. PubMed ID: 11592095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families.
    Li J; Meeks H; Feng BJ; Healey S; Thorne H; Makunin I; Ellis J; ; Campbell I; Southey M; Mitchell G; Clouston D; Kirk J; Goldgar D; Chenevix-Trench G
    J Med Genet; 2016 Jan; 53(1):34-42. PubMed ID: 26534844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No association between MUTYH and MSH6 germline mutations in 64 HNPCC patients.
    Steinke V; Rahner N; Morak M; Keller G; Schackert HK; Görgens H; Schmiegel W; Royer-Pokora B; Dietmaier W; Kloor M; Engel C; Propping P; Aretz S;
    Eur J Hum Genet; 2008 May; 16(5):587-92. PubMed ID: 18301448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simplifying the detection of MUTYH mutations by high resolution melting analysis.
    López-Villar I; Ayala R; Wesselink J; Morillas JD; López E; Marín JC; Díaz-Tasende J; González S; Robles L; Martínez-López J
    BMC Cancer; 2010 Aug; 10():408. PubMed ID: 20687945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low frequency of AXIN2 mutations and high frequency of MUTYH mutations in patients with multiple polyposis.
    Lejeune S; Guillemot F; Triboulet JP; Cattan S; Mouton C; ; Porchet N; Manouvrier S; Buisine MP
    Hum Mutat; 2006 Oct; 27(10):1064. PubMed ID: 16941501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A mutational comparison of adult and adolescent and young adult (AYA) colon cancer.
    Tricoli JV; Boardman LA; Patidar R; Sindiri S; Jang JS; Walsh WD; McGregor PM; Camalier CE; Mehaffey MG; Furman WL; Bahrami A; Williams PM; Lih CJ; Conley BA; Khan J
    Cancer; 2018 Mar; 124(5):1070-1082. PubMed ID: 29194591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cellular and molecular deregulations driving the metastatic phenotype].
    Zeitoun G
    Med Sci (Paris); 2009 Mar; 25 Spec No 1():29-32. PubMed ID: 19361408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.
    Kogita A; Yoshioka Y; Sakai K; Togashi Y; Sogabe S; Nakai T; Okuno K; Nishio K
    Biochem Biophys Res Commun; 2015 Feb; 458(1):52-6. PubMed ID: 25623536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
    Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
    Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
    Moretta J; Berthet P; Bonadona V; Caron O; Cohen-Haguenauer O; Colas C; Corsini C; Cusin V; De Pauw A; Delnatte C; Dussart S; Jamain C; Longy M; Luporsi E; Maugard C; Nguyen TD; Pujol P; Vaur D; Andrieu N; Lasset C; Noguès C;
    Bull Cancer; 2018 Oct; 105(10):907-917. PubMed ID: 30268633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristics.
    Bychkovsky BL; Lo MT; Yussuf A; Horton C; Richardson M; LaDuca H; Garber JE; Rana HQ
    Cancer; 2022 Mar; 128(6):1275-1283. PubMed ID: 34875721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.